基于aptamer的强制酸酶招募基因组抑制受体氨酸激酶信号转导
Shanchao Wu1, Yanxue Shang1, Yuping Yan1
1Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan 410082, People's Republic of China.
Journal of the American Chemical Society
|August 1, 2024
概括
研究人员开发了基于aptamer的新型嵌合体来抑制受体激素酶 (RTK) 酸化,为癌症提供了新的治疗策略. 这些工具招募酸酶以有效调节RTK活动和细胞行为.
科学领域:
- 生物化学
- 分子生物学
- 药物发现
背景情况:
- 异常受体氨酸激酶 (RTK) 酸化驱动瘤的开始,进展和转移.
- 开发有针对性的分子工具来调节RTK酸化是癌症治疗中的一个重大挑战.
研究的目的:
- 设计和验证用于抑制RTK酸化的基于aptamer的新型嵌合体.
- 探索涉及蛋白质氨酸酸酶受体类型F (PTPRF) 的作用机制.
- 建立开发新酸酶招募治疗策略的基础.
主要方法:
- 针对特定RTK (例如c-Met,EGFR) 的基于aptamer的嵌合体的构建.
- 在各种细胞系中抑制RTK酸化的奇默疗效的评估.
- 评估PTPRF招募及其对细胞生物行为的影响.
- 使用DNA复合体确定PTPRF的催化半径.
主要成果:
- 由生长因子或自体二元化诱导的RTK酸化的强烈和通用抑制.
- 通过PTPRF招募, 嵌合体有效调节细胞行为.
- PTPRF的催化半径被精确确定为大约25.84 nm.
结论:
- 这项研究提供了一种选择性控制RTK酸化和细胞过程的多功能方法.
- 开发出基于aptamer的嵌合体为开发新型治疗药物提供了有前途的途径.
- 这项工作为设计先进的酸酶招募策略提供了基础.
相关概念视频
Amplifying Signals via Enzymatic Cascade
8.4K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.4K
Receptor Tyrosine Kinases
12.6K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.6K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Enzyme-linked Receptors
77.8K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.8K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


